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Abstract: The 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole set are well known compounds with interest-
ing in vitro and in vivo anti-cancer profiles. The aim of this study was an in vitro evaluation of the anti-cancer
activity of a new synthesized aminothiadiazole derivative 2-(3-chlorophenyloamino)-5-(2,4-dihydroxyphenyl)-
-1,3,4-thiadiazole 4ClABT. The effect on tumor cell proliferation, motility and morphology, DNA synthesis as
well as the influence on normal cells was assessed. The antiproliferative activity of 4ClABT in tumor cells de-
rived from peripheral cancers including breast carcinoma (T47D), colon carcinoma (HT-29), thyroid carcinoma
(FTC-238), teratoma (P19), and T-cell leukemia (Jurkat E6.1), as well as cancers of the nervous system includ-
ing rhabdomyosarcoma/medulloblastoma (TE671), brain astrocytoma (MOGGCCM) and glioma (C6) was stud-
ied by means of MTT assay. DNA synthesis level was determined in BrdU ELISA test. Wound assay model was
applied for tumor cell motility assessment. Morphological changes induced by 4ClABT in cancer and normal
cells were analyzed in HE staining specimens. Moreover, the influence of 4ClABT on normal cells including
skin fibroblasts (HSF), hepatocytes (Fao), astroglia and neurons was studied by means of LDH assay. The tested
compound inhibited the proliferation of tumor cells in dose-dependent fashion. The anti-cancer effect was at-
tributed to decreased DNA synthesis, prominent changes in tumor cell morphology as well as reduced cell
motility. In antiproliferative concentrations, 4ClABT was not toxic to normal cells. Our study showed prominent
anti-cancer effects of the tested aminothiadiazole derivative in the absence of toxicity in normal cells. The ob-
tained results confirmed the promising anti-cancer profile of previously tested 2-(monohalogenphenylamino)-
-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole derivatives (ClABT — chlorophenyl derivative, FABT and 3FABT
— fluorophenyl derivatives and 4BrABT — bromophenyl derivative). The molecular mechanisms and the in
vivo activity of aminothiadiazole derivatives will be the subject of further studies. (Folia Histochemica et Cytobi-
ologica 2011; Vol. 49, No. 3, pp. 436–444)
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Introduction
Aminothiadiazoles are a series of compounds with
a wide spectrum of biological activity, including anti-
microbial, antiviral, antifungal, antituberculosis, anti-
-inflammatory, anticonvulsant and anti-cancer prop-
erties [1–8]. Their ability to inhibit cancer development
has been documented in numerous in vitro [7–11] and
in vivo [12–18] studies. Their mechanism of action dif-
fers, depending on the type of modification of the thi-
adiazole ring [1, 19–23]. During the second half of the
20th century many different derivatives were synthe-
sized based on this structure. The objects of our inter-
est are 2-amino-1,3,4-aminothiadiazole derivatives.
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In our previous publications, we have described
the synthesis and anti-cancer activity of the members
of 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4-aminothia-
diazole set against various cancer cell lines [24–29].
We have demonstrated the ability of the derivatives
to inhibit cancer cell proliferation and motility, as well
as decrease DNA synthesis. It is important to note
that the tested compounds in anti-cancer concentra-
tions had no influence on the viability of normal cells
[28, 29]. Moreover, a prominent neuroprotective ac-
tivity of 2-(4-fluorophenylamino)-5-(2,4-dihydrox-
yphenyl)-1,3,4-thiadiazole (FABT) has been observed
in the neuronal cultures exposed to neurodegenera-
tive agents [28].
On the basis of QSAR analysis, we aspired to pre-
pare a compound with a preferred anti-cancer pro-
file, high binding efficiency and minimum toxicity.
Nevertheless, the side-effects associated with cancer
chemotherapy are still a serious problem limiting
treatment possibilities. Some 2-amino-1,3,4-thiadia-
zole derivatives were introduced into phase II clini-
cal trials in patients with ovarian, cervical, colon, lei-
omyosarcoma, and other types of cancer. Unfortu-
nately, their application in treatment was limited by
side-effects such as stomatitis, hyperuricemia, leu-
copenia, thrombocytopenia, nausea and vomiting
[14–18]. However, 2-amino-5-(2,4-dihydroxyphenyl)-
-1,3,4-aminothiadiazole synthesized in our research
showed relatively low toxicity for normal cells in in
vitro culture conditions.
The objective of the present study was the evalua-
tion of the activity of 4ClABT in cancer and normal
cells.
Material and methods
Chemical characteristics of 4ClABT. Preparation of com-
pound. The compound was obtained from sulfinyl bis(2,4-
-dihydroxythiobenzoyl) (STB) [30] and 4-(3-chlorophenyl)-
-3-thiosemicarbazide (Lancaster, Germany) or 4-(4-chlo-
rophenyl)-3-thiosemicarbazide (Lancaster, Germany) via
the endocyclization process [24] (Figure 1).
Analytical studies. The melting point (m.p.) was deter-
mined on a BUCHI B-540 (Switzerland) melting point ap-
paratus. Elemental analysis was performed in order to de-
termine C, H and N contents (Perkin-Elmer 2400; USA).
The analyses were within ± 0.4% of the theoretical values.
The vibration spectra were recorded with a Perkin-Elmer
FT-IR 1725X (USA) spectrophotometer in KBr. 1H NMR
and 13C NMR spectra were recorded on a Bruker DRX 500
instrument. Chemical shifts (d, ppm) were given with tet-
ramethylsilane (TMS). The spectra MS (EI, 70 eV) were
recorded using the apparatus AMD-604 (AMD Intectra
GmbH, Germany).
2-(4-chlorophenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4-
-thiadiazole (4ClABT)
Yield: 69%; mp: 249–251°C. 1H NMR (500 MHz, DMSO-
-d6, d): 6.40–6.42 (dd, J = 8.5 Hz and 2.3 Hz, 1H, C5-H), 6.44
-(d, J = 2.3 Hz, 1H, C3-H), 7.37–7.39 (d, J = 8.9 Hz, 2H,
C2’,6’-H), 7.67–7.70 (d, J = 8.9 Hz, 2H, C3’,5’-H), 7.79–7.80
(d, J = 8.6 Hz, 1H, C6-H), 9.89 (s, 1H, NH), 10.37 (s, 1H,
C4-OH), 10.85 (s, 1H, C2-OH); 
13C NMR (125 MHz, DMSO-
-d6, d, ppm): 102.43, 108.12, 108.45, 118.72, 124.84, 128.55,
128.81, 139.77, 155.01 (Cthia-5), 155.68, 160.32, 163.21 (Cthia-2);
IR (KBr, cm-1): 3,314, 3,250 (OH, NH), 1,625 (C = N), 1,601
(C = C), 1,221 (C-OH), 1,105 (C-Cl), 1,011 (N = C-S-C = N),
673 (C-S-C); EI-MS (m/z, %): 319 (M+, 100), 184 (30), 167
(5), 152 (6), 153 (8), 149 (13), 135 (7), 94 (9), 75 (4), 66 (4).
Anal. calcd. for C14H10ClN3O2S (319.77): C, 52.59; H, 3.15;
N, 13.14. Found: C, 52.38; H, 3.14; N, 13.20.
Biological studies. Cell lines. Human leukemic T-cell lym-
phoblast Jurkat E6.1 (Cat. No. 88042803), human breast
carcinoma T47D (Cat. No. 85102201), human colon ade-
nocarcinoma HT-29 (Cat. No. 91072201), human follicular
thyroid carcinoma FTC-238 (Cat. No. 94060902), human
rhabdomyosarcoma/medulloblastoma TE671 (Cat. No.
89071904), human brain astrocytoma MOGGCCM (Cat.
No. 86022702) and rat hepatoma cells Fao (Cat. No.
89042701) were obtained from the ECACC (European
Collection of Cell Cultures, A Health Protection Agency
Culture Collection, Salisbury, UK). Mouse teratoma P19
(Cat. No. CRL-1825) was obtained from the ATCC (Amer-
ican Type Culture Collection, Manassas, VA, USA). Rat
glioma (C6) was obtained from the Department of Neona-
tology, Charite-Virchow Clinics, Humboldt University, Ber-
lin, Germany. Human skin fibroblasts (HSF) were obtained
via the outgrowth technique from skin explants of young
persons. Mouse neurons were differentiated from P19 cells
by way of retinoic acid induction. Rat astroglia was isolated
from the brains of suckling rat pups.
The following culture media purchased from Sigma (Sig-
ma Chemicals, St. Louis, MO, USA) were applied: DMEM
(C6, HSF), 1:1 mixture of DMEM and Nutrient mixture
F-12 Ham (TE671, T47D, HT-29), 3:1 mixture of DMEM and
Figure 1. Synthesis scheme of 2-(4-chlorophenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole (4ClABT)
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Nutrient mixture F-12 Ham (MOGGCCM) and RPMI (Ju-
rkat E6.1), as well as AlphaMEM (P19) and F12 Nutrient
Mixture Kaighn’s (Fao) from Gibco, Life Technologies, Mi-
lan, Italy. All media were supplemented with 10% FBS (Sig-
ma), penicillin (100 U/mL) (Sigma) and streptomycin (100
μg/mL) (Sigma). The cultures were kept at 37°C in a hu-
midified atmosphere of 95% air and 5% CO2.
Neuronal cell culture. P19 cells were cultured in Alpha-
MEM with the addition of 10% FBS. For induction of the
neuronal differentiation, cells were resuspended in Alpha-
MEM medium supplemented with 5% FBS and 0.5 μM re-
tinoic acid at a density of 1 × 107 cells × mL–1. Cells were
incubated for 96 h on Petri dishes (the medium was changed
for a fresh one after 48 h). The obtained neurospheres were
aspirated and centrifuged at 450 rpm for 5 mins, rinsed with
the medium without FBS and centrifuged again. Neuro-
spheres were dispended using 0.01% trypsin-EDTA solu-
tion (10 mins, 37°C) and treated with 0.01% DNAase I in
the presence of 10% FBS to obtain a single cell suspension.
The cells were then sieved through a 40 μM cell strainer
(Falcon, Becton Dickinson Labware, Franklin Lakes, NJ,
USA). Finally, the neurons suspension was centrifuged at
800 rpm for 10 mins and resuspended in culture medium
containing Neurobasal medium (Gibco), 2% B-27 supple-
ment (Gibco), 2 mM L-glutamine (Sigma) and antibiotics
(100 U/mL penicillin and 100 mg/mL streptomycin). The cells
were plated at a density of 4 × 105 × mL–1 on 96-well micro-
plates (Nunc) coated with poly-L-lysine and kept at 37°C in
a humidified atmosphere of 95% air and 5% CO2. The cul-
ture medium was changed every three days. The experiment
was carried out ten days after culture establishment.
Astroglia culture. The primary astrocytes culture was es-
tablished from the cortices of three-day-old Wistar rats. The
brain tissue was pooled into ice cold glucose (33 mM) Hanks’
Balanced Salt Solution (HBSS, Sigma), cut into small piec-
es and incubated for 30 mins at 37°C with 0.25% trypsin-
-EDTA solution. Next, single cells suspension was obtained,
as described for neurons culture. The cells were inoculated
into 75 cm2 cell culture flasks and kept at 37°C in a humid-
ified atmosphere of 95% air and 5% CO2. The cell culture
medium contained a 1:1 mixture of DMEM and Nutrient
mixture F-12 Ham supplemented with 10% FBS and anti-
biotics (penicillin and streptomycin). The medium was
changed every two days until the culture reached confluen-
cy. Next, the flasks were shaken overnight in an orbital shak-
er at 210 rpm in order to remove less adherent cells (neu-
rons, microglia and oligodendroglia). Following this shak-
ing procedure, the culture became enriched with flat cells
displaying typical astrocyte morphology. Immunostaining
with a primary antibody for glial fibrillary acidic protein
(GFAP, polyclonal, DAKO, Denmark) revealed that astro-
cytes accounted for ~95% of the cells in the culture.
Viability assay. Tumor cells were plated on 96-well mi-
croplates at a density of 0.1 × 104 (P19), 0.5 × 104 (C6),
1 × 104 (T47D, TE671, FTC238, MOGGCCM) and 3 × 104
(HT-29) × mL–1. Different cell densities were used de-
pending on the cells’ size and growth rate. Densities
were selected to obtain confluency in control culture af-
ter 96 h. The next day, the culture medium was removed
and the cells exposed to serial dilutions of 4ClABT
(1, 2.5, 5, 10, 25, 50 and 100 μM) in a fresh medium. In the
Jurkat cells culture, 4ClABT was given intermediary to
the cell suspension at a density of 2 × 104 × mL–1. Cell
proliferation was assessed after 96 h using the MTT
method in which the yellow tetrazolium salt (MTT) is
metabolized by viable cells to purple formazan crystals.
The tumor cells were incubated for 3–4 h with MTT
solution (5 mg/mL). Formazan crystals were solubilized
overnight in SDS buffer (10% SDS in 0.01N HCl) and
the product quantified spectrophotometrically by mea-
suring absorbance at the 570 nm wavelength using
a Elx800 microplate reader (BIO-TEK, Highland Park,
Winooski, VT, USA).
Proliferation assay. Cells were plated on 96-well micro-
plates at a density of 1 × 104 (C6) and 2 × 104 (T47D,
FTC238) and 5 × 104 (HT-29) × mL–1. Cell densities were
selected depending on the cells’ size and proliferation rate
to obtain confluency in control culture after 48 h. The next
day, the culture medium was removed and the cells exposed
to serial dilutions of 4ClABT (1, 2.5, 5, 10, 25, 50 and 100 μM)
in fresh medium. Cell proliferation was quantified after
48 h by measurement of BrdU incorporation during DNA
synthesis (Cell Proliferation ELISA BrdU, Roche Diagnos-
tics GmbH, Penzberg, Germany). The test was performed
according to the manufacturer’s instruction. The absorbance
was measured at the 450 nm wavelength using a Elx800 mi-
croplate reader.
Cell migration assessment. Tumor cell migration was as-
sessed by the wound assay model. Glioma C6 cells were plat-
ed at 1 × 106 cells on 3-cm culture dishes (Nunc). The next
day, the cells were scratched by a pipette tip (P300), the
medium and dislodged cells were aspirated, and plates rinsed
twice with PBS. Next, the fresh culture medium was applied
and the number of cells migrated into the wound area after
24 h was estimated in the control and the cultures treated
with 4ClABT (5 and 10 μM). The plates were stained using
the May-Grünwald-Giemsa method. The observation was
performed by a Olympus BX 51 System Microscope (Olym-
pus Optical Co., Ltd, Tokyo, Japan) and the micrographs
prepared by analysis software (Imaging Software Olympus
cell*Family). Cells migrated to the wound area were count-
ed on micrographs and the results expressed as a mean cell
number migrated to the selected 40 wound areas taken from
four micrographs.
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Cytotoxicity assay. Cells were plated on 96-well microplates
at a density of 1 × 105 (HSF, astrocytes) and 2.5 × 105 (Fao)
and 4 × 105 (neurons) × mL–1. Cell densities were selected
depending on the cells’ size to obtain culture confluency
the next day. The following day, the culture medium was
removed and the cells exposed to 4ClABT (1, 2.5, 5, 10, 25,
50 and 100 μM) diluted in a fresh culture medium with
a reduced amount of FBS (2%). Neurons were cultured in
medium with addition of 2% B12 supplement. Cytotoxicity
was detected using an In Vitro Toxicology Assay Kit, Lactic
Dehydrogenase based (Sigma). The assay was based on the
reduction of NAD by the action of lactic dehydrogenase
(LDH) released from damaged cells. The resulting NADH
was utilized in stoichiometric conversion of a terazolium
dye. The resulting colored compound was measured spec-
trophotometrically. The test was carried out according to
the kit procedure. The color product was quantified spec-
trophotometrically at 490 nm wavelength using an Elx800
microplate reader.
Cells morphology. Breast and thyroid carcinoma cells as
well as normal fibroblasts at a density of 5 × 104 (T47D,
FTC238) and 5 × 105 (HSF) × mL–1 plated on Lab-Tek
Chamber Slide (Nunc) were exposed to 4ClABT (5, 10
and 25 μM) in medium with a reduced amount of FBS
(2%). After 48 h, incubation cells were stained using the
Hematoxylin-Eosin (HE) method. The observation was
performed by an Olympus BX 51 System microscope
(Olympus Optical Co., Ltd, Tokyo, Japan) and micrographs
were prepared by analysis software (Imaging Software
Olympus cell*Family).
Results
2-(4-chlorophenylamino)-5-(2,4-dihydroxyphenyl)-
-1,3,4-thiadiazole (4ClABT) (Figure 1) was obtained ac-
cording to the procedure described previously [24, 30].
The anti-cancer effect of the tested compound was
assessed in a range of tumor cell lines, including tu-
mors derived from peripheral cancers (breast carci-
noma, colon carcinoma, thyroid carcinoma, terato-
ma, T-cell leukemia), as well as cancers of the ner-
vous system (rhabdomyosarcoma/medulloblastoma,
brain astrocytoma and glioma). Tumor cells were ex-
posed to either a culture medium (control) or 1, 2.5,
5, 10, 25, 50 and 100 μM of 4ClABT for 96 h and
MTT assay was performed. On the basis of obtained
results, IC50 values for each cell line (Table 1) were
calculated (linear regression analysis of quantal log
dose-probit functions according to the method of
Litchfield and Wilcoxon [31]). The tested compound
produced a 50% viability decrease of tested cancer
cells in the concentration range of 6.4–19.4 μM. The
most sensitive for 4ClABT appeared to be thyroid
carcinoma FTC238 cells and the most resistant were
brain astrocytoma MOGGCCM cells. A higher ac-
tivity of 4ClABT was observed against tumor cells
derived from peripheral cancers than cancer cells orig-
inating from the nervous system.
The effect of 4ClABT on tumor cells was attribut-
ed to decreased DNA synthesis, as determined by
measurements of incorporation of BrdU (Figure 2).
T47D, HT-29, FTC238 and C6 cells were treated with
4ClABT and medium only (control) for 48 h, and then
BrdU assay was performed. ELISA analysis showed
a concentration-dependent decrease of BrdU incor-
poration during DNA synthesis in cells treated with
4ClABT, in comparison to control cells.
In order to evaluate the influence of the tested
aminothiadiazole derivative on cancer cell motili-
ty, the wound assay test was performed (Figure 3).
Glioma C6 cell monolayers were wounded and ex-
posed to 4ClABT for 24 h. The cells were then
stained and analyzed in a light microscope. The
results (Figure 3A) revealed a 27% (5 μM 4ClABT)
and a 42% (10 μM 4ClABT) decrease in the num-
ber of cells migrated to the wound area compared
to the control.
Table 1. Comparison of antiproliferative effect of 4ClABT in tumor cell lines (MTT assay). IC50 was calculated using
computerized linear regression analysis of quantal log dose-probit functions according to the method of Litchfield and
Wilcoxon [31]
Cell culture Histotype IC50 [μM] 4ClABT
FTC238 Thyroid carcinoma 6.4
HT-29 Colon carcinoma 6.5
JurkatE6.1 T-cell leukemia 6.7
P19 Teratoma 8.5
T47D Breast carcinoma 10.7
C6 Glioma 12.7
TE671 Rhabdomyosarcoma-medulloblastoma 15.3
MOGGCCM Astrocytoma 19.4
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Figure 3. Effect of 4ClABT on the migration of glioma C6 cells. Wounded monolayers of glioma cells were incubated
alone (control) and in the presence of 4ClABT (5, 10 μM) for 24 h. Columns show cell number migrated on the wound
area in the control and culture treatment with 4ClABT (A), ***at least p < 0.001, vs. control, One-way ANOVA test,
post-hoc Tukey. Micrograph shows wound assay of C6 cells, wound (B), cell migration after 24 h in control culture (C),
exposure to 5 μM 4ClABT (D) and 10 μM 4ClABT (E). Magnification × 40
Figure 2. The antiproliferative effect of 4ClABT was
attributed to decreased cell division. Human breast
carcinoma (T47D), colon carcinoma (HT-29), follicular
thyroid carcinoma (FTC238) cells and rat glioma (C6) cells
were grown in culture medium only (control) and in the
presence of tested compounds (1–100 μM) for 48 h. BrdU
incorporation was used as a marker of cell division. The
data represents mean normalized optical densities ± SEM
of 3–6 trials and was analyzed by means of linear regression
The effect of 4ClABT on normal human cells was
tested by means of LDH assay. Human skin fibro-
blasts (HSF), rat hepatocytes (Fao), rat primary as-
troglia and mouse neurons were exposed to the
4ClABT (5–100 μM). Next, the level of lactic dehy-
drogenase (LDH) released from damaged cells was
measured after 24 h (HSF, Fao, astrocytes) or 48 h
(neurons) treatment. From our experimental experi-
ence, neuronal cell cultures require longer (48 h) in-
cubation with tested substance or neurodegenerative
agent (e.g. serum deprivation, excitotoxicity) to ob-
serve any remarkable neurotoxic or neurotrophic ef-
fect. For this reason, in neuronal culture a longer in-
cubation time was used.
The obtained results (Figure 4) indicated a lack
of toxic influence of 4ClABT in anti-cancer concen-
trations on the normal cell cultures (skin fibroblasts,
hepatocytes, astrocytes and neurons). Only at very
high 4ClABT concentrations (50–100 μM) was a sig-
nificant increase in the LDH level observed. More-
over, in the cultures of nervous cells (astrocytes and
neurons), a significant decrease of the LDH level was
observed compared to the control (Figures 4C, D).
The influence of 4ClABT on cell morphology was
assessed in cancer and normal cells. Breast carcino-
ma T47D, thyroid carcinoma FTC238 and primary
culture skin fibroblasts HSF were treated with the
tested compound for 48 h and then stained using the
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HE method. The studied derivative at a concentra-
tion of 5–25 μM induced changes in the morphology
of both types of cancer cells, but not in normal cells.
In thyroid FTC 238 cells, 4ClABT produced concen-
tration-dependent cytoplasm shrinkage and an elon-
gated shape of the cells (Figure 5B). Morphological
changes were more prominent in T47D cells (Figure 5A).
We observed a significant cytoplasm shrinkage, inten-
sified with increased 4ClABT concentration, with al-
most complete cell damage at the maximum tested
concentration of 25 μM. However, no toxic effect of
the studied compound was observed in the normal
skin fibroblast culture (Figure 5C).
Discussion
At present, cancerous diseases are one of the most
frequent causes of death worldwide. Despite exten-
sive developments in medicine and the biomedical
sciences, cancer treatment remains a serious prob-
lem. Chemotherapy is usually very aggressive and in-
duces many side-effects. Therefore, the primary aim
of contemporary science and medicine is to develop
a method of treatment with an effective anti-cancer
action which has a low toxicity for normal tissues.
The objects of our scientific interest are aminothi-
adiazoles as potential anti-cancer substances. It is
known that their activity and mechanism of action
depend on the type of modification of the thiadiaz-
ole ring, which is pharmacophore [1, 28]. The anti-
-cancer activity of different derivatives has been doc-
umented in numerous publications [1, 2, 7–13]. Some
of the derivatives were under clinical phase II stud-
ies, but reveal a weak ability for tumor growth inhibi-
tion, and have strong side effects [14–18]. Our 2-ami-
no-1,3,4-thiadiazole derivatives are a very attractive
option among other anti-cancer agents. We have docu-
mented the strong antiproliferative activity of 2-ami-
no-5-(2,4-dihydroxyphenyl)-1,3,4-aminothiadiazole
derivative, concomitant with relatively low toxicity.
We have reported here the action of the 2-(4-chlo-
rophenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4-thia-
Figure 4. Cytotoxicity of 4ClABT in normal human skin fibroblast HSF (A), rat heptocytes Fao (B), rat astroglia (C) and
mouse neurons (D). Cell death in the absence (control) and in the presence of 4ClABT (5–100 μM) was quantified after
24 h (HSF, Fao, astrocytes) and 48 h (neurons) treatment by measuring LDH release. Data represents mean normalized
optical densities ± SEM of 4–6 trials, ***at least p < 0.001, ** p < 0.01, * p < 0.05 vs. control, One-way ANOVA test,
post-hoc Tukey
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diazole (4ClABT) in cancer and normal cells, and the
ability of the tested compound to inhibit prolifera-
tion of different types of cancer cells. It is significant
that cancers of the nervous system (glioma, rhabdomy-
osarcoma/medulloblastoma, astrocytoma) were more
resistant to the action of 4ClABT than cells derived
from peripheral cancers. The obtained results corre-
late with the previously described activity of 2-(4-flu-
orophenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4-thia-
diazole (FABT) [28], 2-(3-fluorophenylamino)-5-(2,4-
-dihydroxyphenyl)-1,3,4-thiadiazole (3FABT), and 2-
(4-bromophenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4-
-thiadiazole (4BrABT) [29]. Their action is simi-
lar, but the intensity of activity seems to depend on
the atom bound to the amino-group. In the screen-
ing studies, chloro-derivatives showed the most in-
teresting anti-cancer properties [24]. Moreover, the
proved inhibition of DNA synthesis by 4ClABT
confirms the ability described by Nelson et al. [10]
of 2-amino-1,3,4-thiadiazole to decrease inosine
5’-phosphate (IMP) dehydrogenase activity. IMP
dehydrogenase is the key enzyme in guanine nu-
cleotides synthesis.
The important activity of 4ClABT, described pre-
viously also for bromo- and fluoro-isomers [28, 29],
is the inhibition of cell motility. The ability to migrate
is an important process in the development of cancer
metastasis. Thus, the discovery of this action makes
4ClABT an attractive  potential anti-cancer agent.
A very interesting point is the activity of the test-
ed compound in normal cells. The performed exper-
iments showed low cytotoxicity of 4ClABT in normal
cells including skin fibroblasts, hepatocytes, astrocytes
and neurons. Additionally, a significant decrease of
the LDH level in astrocytes and neurons after treat-
ment with 4ClABT may suggest a neurotrophic ac-
Figure 5. Effect of 4ClABT on breast carcinoma T47D cells (A), thyroid carcinoma FTC238 cells (B) and normal skin
fibroblasts HSF (C) morphology after 48 h treatment. Micrographs show cells morphology in control culture and exposu-
re to 5 μM, 10 μM and 25 μM 4ClABT; All images at magnification × 100
Control
5 μM
10 μM
25 μM
A B C
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tion of the tested compound. This result confirms the
previously described neuroprotective activity of FABT
[28]. Furthermore, morphological analysis revealed
differences in the action of 4ClABT on cancer and
normal cells. The tested compound, at the same time
exposure and concentration, induced prominent
changes in breast and thyroid cancer cells, but did
not damage normal fibroblasts.
Our results indicate a high level of antiprolifera-
tive activity of 4ClABT. Taking into account its rela-
tively low toxicity, this compound seems to be very
interesting as a potential anti-cancer agent.
The obtained results indicate that aminothiadiaz-
oles act in a specific way affecting rapidly proliferat-
ing cancer cells. Therefore, we are currently investi-
gating the molecular mechanisms of anti-cancer ac-
tivity comprising the influence of tested compounds
on cell cycle regulation, signal transduction pathways
and apoptosis induction. Based on promising prelim-
inary results, the in vivo anti-cancer verification of
tested derivatives will also be performed.
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